Sigma-Aldrich Names Jai Nagarkatti as Chief Executive Officer
News Nov 09, 2005
The Sigma-Aldrich Corporation's Board of Directors has announced the appointment of Jai Nagarkatti, 58, (President and Chief Operating Officer) as President and Chief Executive Officer effective January 1, 2006.
He will succeed Chairman and Chief Executive Officer David Harvey, 66, who will continue to serve as Chairman of the Company's Board of Directors. Jai Nagarkatti was also elected as a member of the Board of Directors.
Speaking on behalf of the Board, David R. Harvey stated, “Jai Nagarkatti is a very seasoned and knowledgeable leader who has had a major impact on the success and growth of Sigma-Aldrich.”
“His experience and insight into our business will serve the Company well as we continue our focus on Life Science and High Technology.”
Jai Nagarkatti noted, “I am pleased by the vote of confidence that the Board of Directors and David Harvey have given me and I look forward to the challenge of accelerating the performance of Sigma-Aldrich and strengthening the Company's position as a worldwide leader in our research and fine chemical businesses.”
The 29-year Sigma-Aldrich career of Jai Nagarkatti has spanned R&D, production, operations and sales and marketing.
Since August 2004, he has been Chief Operating Officer and President. Previously he served as the President of the largest research division and the fine chemicals business.
Jai Nagarkatti, a U.S. citizen, was born in Hyderabad, India. He obtained his Master's degree in chemistry at Osmania University in Hyderabad and subsequently a Ph.D. in organic chemistry at Texas A&M University.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.